Beijing Balance Medical Technology (SHA:688198), through subsidiary Beijing Aibairui Biotechnology, received China's National Medical Products Administration approval for Collagen Fiber Filler-I, according to a Thursday disclosure on the Shanghai bourse.
The product is the first cross-linked collagen implant in China, the company said.
The filler is primarily intended for injection to correct moderate to severe nasolabial fold wrinkles.
The pharmaceutical company's shares rose 1% at the close.